Last reviewed · How we verify
Mepolizumab 100 MG
At a glance
| Generic name | Mepolizumab 100 MG |
|---|---|
| Also known as | Nucala, nucala |
| Sponsor | Università degli Studi di Ferrara |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Aggravated Airway Inflammation: Research on Biological Treatment (Mepolizumab) (PHASE4)
- Efficacy of Mepolizumab in Polish Patients With Severe Eosinophilic Asthma
- Safety and Efficacy of Meplazumab in Patients With Coronary Artery Disease (PHASE2)
- Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA (PHASE4)
- Anti-IL-5 Therapy With Simple Polypectomy Versus Extended Endoscopic Sinus Surgery for CRSwNP (PHASE4)
- Mepolizumab in Chronic Obstructive Pulmonary Diseases (COPD) With Eosinophilic Bronchitis (PHASE3)
- Tapering of Biologics in Chronic Rhinosinusitis With Nasal Polyps (PHASE4)
- Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mepolizumab 100 MG CI brief — competitive landscape report
- Mepolizumab 100 MG updates RSS · CI watch RSS
- Università degli Studi di Ferrara portfolio CI